Imperial College Healthcare Nhs Trust - Hammersmith Hospital

London W12OHS

7 studies enrolling now · 37 studies all time

What they study most

Adenocarcinoma, Pancreatic Ductal, Advanced Solid Tumors, Anal Carcinoma, Anemia, Hemolytic, BRAF V600E-mutant Metastatic Colorectal Cancer, Basal Cell Carcinoma (Unresectable or Metastatic), Beta-Thalassemia, Bladder Cancer, Castration Resistant Prostate Cancer, Cervical Cancer, Chronic Graft-versus-host Disease, Churg Strauss Syndrome

Studies at this site

• A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections — Recruiting now
• Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) — Recruiting now
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC — Recruiting now
• Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) — Recruiting now
• Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma — Recruiting now
• A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
• Lead Evaluation for Defibrillation and Reliability Post Approval Study — Enrolling by invitation
• A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) — Running, not enrolling
• Study of INCB123667 in Subjects With Advanced Solid Tumors — Running, not enrolling
• Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) — Running, not enrolling
• A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — Running, not enrolling
• A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia — Running, not enrolling
• Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Running, not enrolling
• Personalized Therapy Study - Attain Stability Quad Post-Approval Study — Running, not enrolling
• A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia — Completed
• Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031 — Stopped early
• Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) — Stopped early
• Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS) — Running, not enrolling
• GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Stopped early
• Personalized Therapy Study - HFRS (TriageHF) Post Approval Study — Running, not enrolling
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors — Stopped early
• Study of INCA 0186 in Subjects With Advanced Solid Tumors — Stopped early
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma — Stopped early
• A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease — Completed
• A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors — Completed
• INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors — Completed
• Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) — Stopped early
• Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma — Completed
• A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma — Completed
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
• A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) — Completed
• A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion — Completed
• Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib — Completed
• A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) — Completed
• A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) — Completed
• American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis — Status unconfirmed